Screener
Pfizer PFE Restructuring Charges
Discontinued — last reported Q1 '24
Restructuring Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Pfizer’s 10-Q, filed May 8, 2024.
- Filed
- May 8, 2024
- Fiscal quarter
- Q1 FY2024
- Calendar quarter
- Q1 2024
- Accession
- 0000078003-24-000107
| The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives: / (MILLIONS) | Three Months Ended / March 31,2024 | April 2,2023 |
|---|---|---|
| Employee terminations | $(29) | $(36) |
| Asset impairments | 25 | (10) |
| Exit costs | 14 | 2 |
| Restructuring charges/(credits)(a) | 10 | (44) |
| Transaction costs(b) | 5 | — |
| Integration costs and other(c) | 87 | 52 |
| Restructuring charges and certain acquisition-related costs | 102 | 9 |
| Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net | 3 | (5) |
Item 1.
FAQ
- What is Pfizer's restructuring charges?
- Pfizer (PFE) reported restructuring charges of $10M in Q1 2024.
- How has Pfizer's restructuring charges changed year-over-year?
- Pfizer's restructuring charges increased by 122.7% year-over-year, from -$44M to $10M.
- What does restructuring charges mean?
- One-time costs from reorganizing operations, including employee severance, facility closure costs, contract termination fees, and asset relocation expenses.
Ask your AI about Pfizer's restructuring charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude